The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Biosimilars Are Slowly Climbing Toward Acceptance in Rheumatology

Biosimilars Are Slowly Climbing Toward Acceptance in Rheumatology

June 15, 2020 • By Bryn Nelson, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

As useful stand-ins for biologics targeting a range of inflammatory diseases, biosimilars have made significant inroads across Europe as less expensive alternatives. Denmark, for example, realized a cost savings of 64% after instituting a mandatory national switch from the originator infliximab to its biosimilar counterpart.

You Might Also Like
  • Biosimilars to Raise Unique Questions
  • Remicade Antibodies Cross-React to Biosimilars
  • The Science Behind Biosimilars
Explore This Issue
June 2020

In the U.S., however, a considerably smaller fraction of rheumatologists are prescribing these biologic alternatives to their patients. Increasing the trend, and realizing the expected cost savings that have, thus far, largely failed to materialize, experts say, will depend upon the resolution of multiple pricing, clinical, regulatory and educational barriers.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

A recent analysis in Arthritis & Rheuma­tology crystalized the lopsided U.S. market.1 The researchers pored over roughly 1.1 million tumor necrosis factor inhibitor prescriptions or infusions from Jan. 1, 2016, to March 31, 2019, in a large commercial insurance database. The study reviewed the uptake of the biosimilars infliximab-dyyb, developed by Celltrion and marketed as Inflectra in November 2016, and infliximab-abda, launched as Renflexis by Samsung Bioepis in July 2017. Together, the two biosimilars accounted for just 0.9% of market share through the first quarter of 2019.

The amount paid by the insurer for the biosimilars vs. the biologic originator began to diverge only in the third quarter of 2018. The widening gap in cost was perhaps triggered by the arrival of unique Healthcare Common Procedure Coding System codes and, thus, the ability of biosimilar manufacturers to finally compete, the study authors suggest. The modest savings, though, may have reflected “the smaller purchasing power of US payers relative to single payer systems,” they concluded.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Study co-author Seoyoung Kim, MD, ScD, associate professor of medicine at Brigham and Women’s Hospital, Boston, says that without a substantial difference in cost, “there is no huge incentive for patients or physicians or healthcare systems to use biosimilar infliximab vs. [the] branded one.” Significantly larger savings, she and her colleagues maintain, may require more systemic changes to the nation’s pharmaceutical market.

An editorial commenting on Dr. Kim’s study noted that of the 13 biosimilars approved by the U.S. Food & Drug Administration (FDA) with indications for rheumatic diseases, only two had reached the commercial market by January 2020.2 Inflectra (infliximab-dyyb) and Renflexis (infliximab-abda) are competing against Remicade (infliximab), while a third biosimilar, Pfizer’s Ruxience (rituximab-pvvr), is expected to become available later this year.

“In other words, biosimilars have largely failed to launch in the United States,” writes Jinoos Yazdany, MD, MPH, professor of medicine and chief of the Division of Rheumatology at Zuckerberg San Francisco General Hospital.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

In fact, as spending on biologic drugs reached $125 billion per year in the U.S. in 2018, with Humira (adalimumab) sales alone representing $18 billion of that total, biosimilars were netting only 9% of the initial $1 billion in savings projected by the Congressional Budget Office.

Pages: 1 2 3 4 5 | Single Page

Filed Under: Biologics & Biosimilars, Research Reviews Tagged With: Arthritis & Rheumatology, drug costs, infliximabIssue: June 2020

You Might Also Like:
  • Biosimilars to Raise Unique Questions
  • Remicade Antibodies Cross-React to Biosimilars
  • The Science Behind Biosimilars
  • FDA Approves Biosimilar to J&J’s Remicade for Multiple Diseases

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)